Leonteq Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$134K Buy
32,560
+30,000
+1,172% +$102K 0.01% 598
2026
Q2
$9.4K Sell
2,560
-20,000
-89% -$66.6K ﹤0.01% 1032
2026
Q1
$69.3K Sell
22,560
-102,069
-82% -$394K ﹤0.01% 805
2025
Q4
$510K Buy
124,629
+57,630
+86% +$285K 0.02% 456
2025
Q3
$327K Buy
66,999
+2,000
+3% +$10.5K 0.01% 502
2025
Q2
$329K Buy
64,999
+57,569
+775% +$283K 0.01% 460
2025
Q1
$39.2K Buy
7,430
+2,499
+51% +$18.2K ﹤0.01% 868
2024
Q4
$33.3K Sell
4,931
-9,804
-67% -$65.9K ﹤0.01% 900
2024
Q3
$97.1K Buy
14,735
+2,000
+16% +$14.3K 0.01% 627
2024
Q2
$95.5K Sell
12,735
-4,500
-26% -$39.2K 0.01% 636
2024
Q1
$172K Buy
+17,235
New +$192K 0.01% 529

Other funds holding RXRX

Leonteq Securities's RXRX Position: Q3 2026 in Review

Leonteq Securities increased its Recursion Pharmaceuticals (RXRX) stake by 1,172% in Q3 2026, buying an estimated $102K and bringing the position to 32,560 shares worth $134K. The position accounts for 0.01% of the portfolio, ranked #598.

Leonteq Securities first reported a position in RXRX in Q1 2024 and has held it in 11 quarters since. The position peaked at $510K in Q4 2025. 341 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Leonteq Securities held 32,560 shares of Recursion Pharmaceuticals worth $134K as of Q3 2026.
  • Leonteq Securities bought 30,000 Recursion Pharmaceuticals shares in Q3 2026, an estimated $102K.
  • Recursion Pharmaceuticals made up 0.01% of Leonteq Securities's portfolio in Q3 2026, its #598 holding.
  • Leonteq Securities first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
  • Leonteq Securities's Recursion Pharmaceuticals position peaked at $510K in Q4 2025.
  • 341 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.